Loading..
  • Vivesto logo
  • Vivesto logo
Vivesto
  • About Us
  • Technology & Pipeline
  • Governance
  • Investors
  • Media
  • Contact
  • About Us
    • CEO corner
    • Organisation
      • Management
      • Board of Directors
    • Partnering
    • Career
      • Vacant positions
    • Sustainability / Corporate Responsibility
  • Technology & Pipeline
    • XR-17 Technology Platform
      • Benefits
      • Therapeutic focus
      • IP protection
    • Commercialized products
      • Apealea
    • Project Pipeline
      • Cantrixil
      • Docetaxel Micellar
    • Research and development
      • XR-18
      • XR-19
    • Animal Health
  • Corporate Governance
    • Governance reports
    • General Meeting
    • Management
    • Board of Directors
    • Nomination Committee
    • Remuneration
    • Auditor
    • Code of Conduct
    • Articles of Association
    • Documents
  • Investors
    • Key value drivers
    • The Share
    • Ownership Structure
    • Financial Reports and Presentations
    • Analyst coverage
    • Prospectuses
    • Archive US listing
      • SEC Filings
      • Info regarding delisting of ADS from NASDAQ US
    • Press releases
    • Financial calendar
    • Subscribe
    • Contact
  • Media
    • Press releases
    • Presentations
    • Events
    • Subscribe
    • Image Bank
    • Contact
  • Contact

Press releases

All releases
  • Regulatory Releases
  • Press Releases
2018
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • All years
Regulatory
December 17, 2018

Clarification from the Board of Directors and Management of Oasmia Pharmaceutical AB (publ), “Oasmia” due to Per Arwidsson’s and Arwidsro Investment AB’s request for convening an Extraordinary General Meeting

Regulatory
December 14, 2018

NOTICE OF EXTRAORDINARY GENERAL MEETING IN OASMIA PHARMACEUTICAL AB (PUBL)

Regulatory
November 30, 2018

Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)

Regulatory
November 30, 2018

Oasmia Pharmaceutical AB (publ)

Regulatory
November 29, 2018

Oasmia Pharmaceutical AB announces new agreement with Baxter Oncology GmbH for global commercial manufacturing of Apealea®

Regulatory
November 28, 2018

Oasmia intends to issue notice to an extraordinary general meeting at the request of a shareholder and announces that it is subject to legal proceedings with a major shareholder concerning the company’s warrants 2018/2019

Regulatory
November 22, 2018

Oasmia Pharmaceutical Receives Approval from European Commission for Apealea® (paclitaxel micellar) in the European Union

Regulatory
November 20, 2018

New U.S. patent related to Oasmia Pharmaceutical’s nanotechnology platform XR-17 has been granted

Regulatory
November 1, 2018

Oasmia completes a private placement of new convertible instruments in the amount SEK 80 million

Non Regulatory
October 31, 2018

Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)

Regulatory
October 3, 2018

Oasmia Presents Positive Efficacy and Safety Data for Doxophos Vet in Treatment of Naïve Dogs with Lymphoma

Regulatory
September 30, 2018

Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)

Regulatory
September 25, 2018

Annual General Meeting of Oasmia Pharmaceutical AB (publ) held on 25 September 2018

Regulatory
September 21, 2018

Oasmia Pharmaceutical Receives Positive CHMP Opinion for Apealea® (paclitaxel micellar) in the European Union

Regulatory
September 18, 2018

Update regarding the Market Authorization Application of Apealea in the European Union

Regulatory
September 7, 2018

Oasmia completes a private placement of new convertible instruments in the amount SEK 35.2 million

Non Regulatory
August 31, 2018

Oasmia Pharmaceutical AB (publ)

Non Regulatory
August 30, 2018

Notification from Oasmia Pharmaceutical AB

Regulatory
August 24, 2018

Oasmia Pharmaceutical publishes the Annual Report for 2017/2018

Non Regulatory
August 24, 2018

NOTICE OF ANNUAL GENERAL MEETING IN OASMIA PHARMACEUTICAL AB

Non Regulatory
August 1, 2018

Notification from Oasmia Pharmaceutical AB

Regulatory
July 31, 2018

Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)

Regulatory
July 27, 2018

Status of the Market Authorisation Application of Apealea in the European Union

Regulatory
July 27, 2018

Status of Orphan designation of Apealea in the European Union

Regulatory
June 8, 2018

Oasmia Pharmaceutical AB (publ) Year-end report for the financial year May 1, 2017 – April 30, 2018

Regulatory
June 5, 2018

Results from Oasmia Pharmaceutical’s phase III study have been presented at ASCO annual meeting

Regulatory
May 30, 2018

Nexttobe Extends Loan to Oasmia Pharmaceutical

Regulatory
May 21, 2018

Oasmia Pharmaceutical Completes Spin-off of Veterinary Oncology Assets to Wholly Owned US Subsidiary, AdvaVet, Inc.

Regulatory
May 17, 2018

Results from Oasmia Pharmaceutical’s phase III study will be presented at ASCO annual meeting in June

Non Regulatory
May 16, 2018

Notification from Oasmia Pharmaceutical

Non Regulatory
May 8, 2018

Notification from Oasmia Pharmaceutical AB

Non Regulatory
May 2, 2018

Notification from Oasmia Pharmaceutical AB

Non Regulatory
April 24, 2018

Notification from Oasmia Pharmaceutical AB

Regulatory
April 19, 2018

Oasmia has completed a private placement of new convertible instruments in a total amount of SEK 26,000,000

Non Regulatory
March 2, 2018

Oasmia Pharmaceutical AB (publ)

Regulatory
February 19, 2018

Oasmia Pharmaceutical’s Docecal program achieves significant development milestone

Regulatory
January 24, 2018

Directed issue of warrants in Oasmia Pharmaceutical AB

Regulatory
January 2, 2018

Oasmia Pharmaceutical Secures Financing of 108 MSEK

Investor contact
[email protected]
+46 18-50 54 40

Subscribe to our news

  • Media
    • Press releases
    • Presentations
    • Events
    • Subscribe
    • Image Bank
    • Contact
Vivesto logo
  • About Us
  • Technology & Pipeline
  • Corporate Governance
  • Investors
  • Media
  • Contact

Vivesto AB is a specialty pharmaceutical company focused on thedevelopment of new therapeutic options for patients suffering from hard-to-treatcancers. It has an emerging pipeline of clinical-stage assets targeting late-stagecancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancerpatients through a partnership with Elevar Therapeutics, Inc. Development programsinclude Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxelmicellar, in development for advanced prostate cancer. Vivesto has proprietary drugdelivery technology designed to improve solubility, efficacy and safety.

The Share

Follow the share
  • Personal data
  • Cookies

OAS-MA-P-001-SEP2020

Vivesto AB
Vallongatan 1
SE-752 16 Uppsala
Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@vivesto.com